Brand Exclusivity Increases: Incentivizing Innovation, Or Leading America To Ruin?
This article was originally published in The Pink Sheet Daily
House Energy and Commerce’s 21st Century Cures Initiative hears arguments for why exclusivity reform is necessary, but Rep. Waxman argues that more research about its impact on drug discovery is needed first.
You may also be interested in...
Granting payers more conditional coverage authority may be necessary for legislation to succeed at accelerating biomedical innovation, the former CMS CMO argues, but industry may not be on board.
House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.